NEWS
Posters & Presentations
Navigator Medicines at the 2025 AAD Annual Conference
A First-in-Human Phase 1a Randomized, Double-Blind, Single-Ascending Dose Study of NAV-240, an anti-OX40L/TNFα Bispecific Antibody, in Healthy Volunteers
>> VIEW POSTER